Last edited 10/2020 and last reviewed 09/2022
- induction treatment for most patients with ANCA associated vasculitis (AAV) should be with cyclophosphamide or rituximab and glucocorticoids
- AAV should be considered to be a chronic disease needing longterm immunosuppressive therapy
- rituximab should be considered as an alternative induction agent for those at high risk of infertility and infection
- mortality remains high, and late death is due to cardiovascular disease, infection (secondary to treatment) and malignancy
- molecules other than anti-
TNF agents and rituximab, such as abatacept, mepolizumab (an
anti-IL5 antibody) and alemtuzumab (a humanised monoclonal
anti-CD52 antibody) have been used in refractory cases of AAV (4)
- a systematic review "...found moderate-certainty evidence that in patients with relapsing or refractory EGPA, mepolizumab compared to placebo probably
decreases disease relapse and low-certainty evidence that mepolizumab may increase the probability of accruing at least 24 weeks of
- Davies DJ. Small vessel vasculitis. Cardiovascular Pathology 2005; 14 (6): 335-346.
- ARC Autumn 2012. Topical Reviews - ANCA-associated vasculitis; 1:1-12.
- Yates A, Watts R. ANCA-associated vasculitis. Clinical Medicine 2017 Vol 17, No 1: 60–4
- Bala MM et al.
Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Cochrane Database of Systematic Reviews 2020, Issue 9. Art. No.: CD008333.